Equity Overview
Price & Market Data
Price: $0.23
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $489,881,600
Volume: 0
Performance Metrics
1 Week: -8.00%
1 Month: 4.55%
3 Months: 6.98%
6 Months: 3.60%
1 Year: 2,606%
YTD: -8.00%
Details
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia and the United States. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in West Perth, Australia.